Tasfygo (tasurgratinib)

News alerts, weekly reports and conference planners

Company:

Eisai

Drug class:

FGFR inhibitor

Related drugs:

FGFR mutation	Breast Cancer	FGFR mutation	Breast Cancer	tasurgratinib Sensitive: D – Preclinical tasurgratinib Sensitive : D	tasurgratinib Sensitive: D – Preclinical tasurgratinib Sensitive : D
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	tasurgratinib Sensitive: D – Preclinical tasurgratinib Sensitive : D	tasurgratinib Sensitive: D – Preclinical tasurgratinib Sensitive : D

Associations
(2)